EGFR and cholangiocarcinoma: Another study demonstrated that EGFR-CAR-T cell infusions in phase 1 clinical trial for patients with BTC, including CC, have a safe and improved clinical outcome (ClinicalTrials.gov identifier: NCT01869166); 6% (1/17) and 58.8% (10/17) of these patients had CR for 22 months and SD for 2.5 to 15 months, respectively [134].